European Biotechnology News Special 08/2013 - Preview: Euro BioFairs Compass

European Biotechnology News Science & Industry

August 2013

II Euro BioFairs Compass

SPECIAL 31_EBSIN8_13_SPECIAL_Titel_Compass_Herbst 2013_tg.indd 27

08.08.2013 15:00:53 Uhr

European Biotechnology Net work

Join the European Biotechnology Network!

The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe. This non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.

Do you want to know more about the advantages of a (free) membership? Just have a look at our website: www.european-biotechnology.net

European Biotechnology Network | Avenue de Tervueren 13 | 1040 Brussels, Belgium Tel: +32 2 733 72 37 | Fax +32 2 64 92 989 info@european-biotechnology.net | www.european-biotechnology.net

32_EBSIN8_13_EBN.indd 1

08.08.2013 15:01:07 Uhr

Nº 8 | Volume 12 | 2013

Euro|Biotech|News

33

Euro Biofairs Compass Intro

Finding new partners and technologies An impressive number of life sciences events are scheduled for Europe’s 2013 conference season. From partnering to scientific congresses, from product shows to technology offerings – this autumn is one long series of highlights that could impact your business. Whether you are looking for a licensing partner, need financing or just want to find out more about the latest developments in R&D equipment and services, you’ll find everything you need to know about what each event provides in this issue of the EuroBiotechNews.

With its International Pharma Licensing Symposia (IPLS) the European Pharma­ ceutical Licensing Group network offers unrivalled access to the business devel­ opment community in Europe. This year’s event, which will be held from the 18-20 September (see p. 34) in the Irish capital Dublin will bring together some 250 dele­ gates who work in business development for networking and discussion of the lat­ est trends in the field.

The latest trends in lab equipment and bio­tech applications will be showcased in

Hanover, where the biennial BIOTECHNICA conference and trade fair will take place from 8-10 October. There four conference streams called ’marketplaces’ will reflect the latest industry and funding trends, among them Personalised Medicine Tech­ nologies, Innovation in Food, Industrial Biotechnology (or bioeconomy, the main topic at the fair) and BioServices (for biopharmaceutical drug development). This year, the Swiss biotech sector – one of the most productive in Europe – will be at the centre of focus.

Huge fairs and highly specific events – Europe’s biotech sector now has them all.

33_EBSIN8_12_SPECIAL_intro1_tg.indd 33

And this autumn the Polish city of Gda´nsk will also become a meeting point for entre­ preneurs, young scientists, Big Pharma and funding experts. Formerly two events, the ScanBalt Forum and Bioinnovation Inter­ national Summit have now merged to pro­ duce the Bioinnovation ScanBalt Forum, taking place on the 16-18 October in the halls of the Polish Baltic Frédéric Chopin Philharmonic. The conference is dedicated to rapid scientific change, grant opportuni­ ties and collaborations, biotechnology, life science and bio-business in Poland, Europe and the US. The Bioinnovation ScanBalt Fo­ rum is designed to meet the needs of am­ bitious young PhD students and scientists looking for investors and partners for their ideas. The event also targets biotech and life sciences companies, as well as anyone who is interested in trends in biotechnology and innovations for a healthy life.

New partners and new markets Europe’s largest partnering conference serving the global biotechnology indus­ try – the BIO-Europe – will take place in Austria’s vibrant biocluster Vienna this year from the 4-6 November (see p. 40). In 2012, the EBD Group’s networking system partnering­One® scheduled 15,276 one-toone meetings there. The BIO-Europe is where the continent’s bio­pharmaceutical scene comes to negotiate new licensing agreements.

And in early December, when Europe is setting in for the long, dark winter, it makes sense to head for warmer climes.

That’s when the Colombian capital Bo­ gotá will host the BIO­LATAM 2013 part­ nering event and conference for the very first time. Its aim is to grow into the pre­ mier event focussed on Latin American biotechnology by combining conferences, business meetings and networking events to facilitate contacts between international companies, investors, entrepreneurs and research centres in the life sciences field.

Attendance at the first event is expected to exceed 500 delegates from 20 countries.

Following a session on VC, agri­cultural products will be in the limelight, along with business opportunities in the fields of bio­ fuels and bioplastics.

B

08.08.2013 15:05:02 Uhr

34

Nº 8 | Volume 12 | 2013

Euro|Biotech|News

Euro Biofairs Compass

September 18 – 20, 2013 Ballsbridge Hotel Dublin / Republic of Ireland

XI International Pharma Licensing Symposium

IPLS: Maith thú!

With its International Pharma Licensing Symposia, the Pharmaceutical Licensing Group network offers unrivalled access to the business development community in Europe.

This year’s event, held in Ireland’s capital city Dublin, will once again bring together some 250 delegates who work in the field. If the 11th IPLS delivers on its promise, delegates will sum it up as they did the first 10 events: Maith thú – “well done!”

The programme will be split into sections, with each section featuring three presentations from experts in the relevant field focusing on a particular theme.

With sessions on the Financing of Deals, Personalised Medicine as well as Mid- to Late-Stage Licensing, IPLS has put three of the hot topics in business development on the agenda. In addition, there will be six workshops spread over two days on a range of subjects that will offer further insight and debate through interactive sessions. Among others, topics will include a session on emerging markets, deal issues like spin-outs and valuation forecasting, as well as case studies of recent successful deals.

A feature that distinguishes IPLS from other congresses is the informal and relaxed nature of the networking opportunities throughout the event. Extended breaks, a Welcome Drinks Reception, and an opulent Gala Dinner leave plenty of space for delegates to make contact with both new acquaintances and old friends. B

The IPLS meetings have proven to be valuable symposia for all those involved in business development and licensing throughout Europe and the world. Licenses are the lubricants that keep the pharmaceuticals business up and running.

Pharma giants in-license new active ingredients to fill clinical pipelines, while young start-ups out-license products to generate milestone payments and royalties to fuel business.

Themed “Business Development: From Molecule to Market... and Beyond!”, this year’s IPLS will once again address major topics in the healthcare licensing area. The three-day conference programme has been put together by senior industry professionals from across Europe to ensure that the presentations are both topical and varied, with key industry speakers providing their views and opinions.

Greeting

programme “From Molecule to Market… and Beyond”, will explore all aspects of the industry, through presentations and workshops delivered by respected industry figures. With delegates from across Europe, China and the US, networking is a key part of the symposium. One-to-one meetings can be arranged via the preevent online contact system, as well as during the event.

› Quick facts

Thomas Högn Chairman European Pharma Licensing Council

admin@plg-uk.com www.plgeurope.com/Dublin_2013

From molecule to market and beyond The 11th IPLS brings together those involved within business development and licensing through the pharmaceutical and healthcare industry. The three-day

34_EBSIN8_13_SPECIAL_IPLS_2013_bk.indd 34

Focus Themes Financing of Deals Personalised Medicine Mid-Late Stage Licensing Partnering Highlights Online Delegate Contact System Networking Events

08.08.2013 15:02:23 Uhr

Life Sciences.

Living Research.

Berlin. Brandenburg.

A vibrant network.

Berlin-Brandenburg is one of Europe’s leading locations for the Life Sciences. It is also an R&D capital that magnetically attracts the world’s top scientists. Here you’ll nd attractive subsidy conditions, close linkages between business and science, the highest concentration of R&D in Europe, a dynamic startup scene and a multifaceted entrepreneurial environment made up of more than 500 pharmaceutical, biotech and medical engineering companies. Come discover this one-of-a-kind landscape for scientists and entrepreneurs. www.businesslocationcenter.de/healthcareindustries www.zab-brandenburg.de/en/ClustersIndustries Visit us at Biotechnica 2013!

October 08 – 10, Hannover, Hall 09, Booth D33

210x275_EBN_Biotech_en_Arial_rz_4.indd 5 35_EBSIN8_13_BerlinPartner.indd 1

02.08.13 12:18 08.08.2013 15:02:42 Uhr

36

Nº 8 | Volume 12 | 2013

Euro|Biotech|News

EUro Biofairs compass

October 8 – 10, 2013 Messe Hannover Hanover / Germany

BIOtechnica 2013

Greeting

Jubilee in Hanover

Europe’s central biotech hub

The BIOTECHNICA is celebrating its 20th jubilee this year – a good occasion to make a few changes to the traditional biotech meeting. Visitors to the three-day trade fair can look forward to numerous innovations. Switzerland is the first official partner country of the BIOTECHNICA. Additionally, the organisers have enhanced the exhibition with four marketplaces.

In previous years, Switzerland has been one of the largest national exhibitors at the fair, and this year it will be the first official partner country of the traditional biotech meeting. Many of Switzerland’s 240 biotech companies – as well as ma­ jor Swiss regions – will be presented in the Swiss Pavilion. Director of the Swiss Biotech Association Domenico Alexakis explains why the country became a part­ ner: “We want to use our presence as a

› Quick facts Numbers In 2011, more than 11,000 people vis­ ited the BIOTECHNICA. 618 exhibitors from 28 nations attended the trade fair.

Innovations Official Partner Country: Switzerland Four market places: Personalised Medicine Technologies, Innovation in Food, Industrial Biotechnology and BioServices.

36_EBSIN8_13_SPECIAL_biotechnica_al.indd 36

partner country to demonstrate the great potential and innovative strength of the Swiss biotech industry.”

Another innovation at this year’s BIO­ TECHNICA is four themed market­places: Personalised Medicine Technologies, Innovation in Food, Industrial Biotech­ nology and BioServices. The Personal­ ised Medicine Technologies marketplace covers molecular diagnostics and relat­ ed individualised therapeutic approach­ es. Under the motto ’Innovation in Food’, the BIOTECHNICA will continue to ex­ pand the choice on offer in the category of Food Biotechnology. Here, as with the Industrial Biotechnology marketplace, the thematic emphasis is on the bioecono­ my – also this year’s official main subject area. This includes a showcase of inno­ vative products, as well as the Biobased­ World, which aims to connect key stake­ holders in the biobased economy across various sectors and disciplines. The fourth area of BioServices will bring to­ gether pharma and biotech companies with highly specialised services for biopharmaceutical drug development. B

With an attractive array of new top­ ic s and inno v a ­ tive marketplaces, BIOTECHNICA 2013 in Hanover, Germany, will host the European bio­ tech community and its clientele from 8-10 October 2013. For the twentieth time, the trade fair will serve as Europe’s cen­ tral hub for biotech networking, business and collaboration.

The upcoming event will highlight all the latest R&D innovations and advances, as well as the many products and applica­ tions for biotechnology in medicine, agri­ culture, food production, industry and en­ vironmental protection. Attendees can also acquaint themselves with a wide range of related services for biotech and pharmaceutical requirements. Among the keynote themes to be featured at the 2013 show is bio-economics.

We very much look forward to seeing you in Hanover next October. Please come and join us as we explore the future of biotech­ nology together!

Dr. Jochen Köckler Member of the Managing Board Deutsche Messe AG 30521 Hanover Germany

09.08.2013 13:00:22 Uhr

Technopol Krems - BioTec Area Krems Excellent equipped laboratories including GMP/GLP clean room technology and generous office space.

Krems as Biotech Area offers sites for research and development, partnering and cooperation support wirth local research institutes an universities.

Krems Biotec Area research focus:  Blood purification systems  Tissue engineering (biocompatible materials)  Cell therapy  Cell biology and cellular physiology

Companies/Organisations on site:

ecoplus. The Business Agency of Lower Austria For further information please contact v.ossmann@ecoplus.at or office@biotec-area-krems.at 37_EBSIN8_13_EcoPlus.indd 1

The Technopol Program of Lower Austria is co-financed by the European Regional Development Fund (ERDF) and the province of Lower Austria.

08.08.2013 15:03:51 Uhr

38

Nº 8 | Volume 12 | 2013

Euro|Biotech|News

Euro Biofairs Compass

October 16 – 18, 2013 Polish Baltic Frédéric Chopin Philharmonic, Gda´nsk, Poland

Bioinnovation & ScanBalT Forum

Innovative ScanBalt Continuous development of the conferences joined under the Bioinnovation brand has allowed the organisers to set ambitious new goals. This year’s conference is dedicated to rapid scientific changes, grant opportunities and collaborations, biotechnology, life science and bio-business in Poland, Europe and the US. The Bioinnovation ScanBalt Forum is de­ signed to meet the needs of ambitious young PhD students and scientists looking for investors and partners for their ideas.

The event also targets biotech and life sci­ ences companies, as well as everyone who is interested in news and trends in biotech­ nology and innovations for a healthy life.

Professor Charles Cantor, the Chief Sci­ entific Officer of Sequenom Inc. and author of the first genomics handbook entitled “Ge­ nomics: The Science and Technology Be­

hind the Human Genome Project” will be the keynote speaker at the Bioinnovation & ScanBalt Forum 2013. And there will be many other interesting speakers from the US and Europe as well, including repre­ sentatives from biotech companies like Olink, Novo Nordisk and Dupont.

To maintain the event’s high standards, the organising committee includes repre­ sentatives from the Intercollegiate Faculty of Bio­technology of the University of Gda´ nsk and the Medical University of Gda´ nsk, Scan­

Greetings

Forum 2013. It merges the ScanBalt Fo­ rum and Bioinnovation International Sum­ mit and provides unique opportunities to establish cooperations between life scienc­ es companies, researchers and technology brokers. This unique conference is taking place in the Polish Baltic Frédéric Chopin Philharmonic. We would be delighted to welcome you from 16-18 October in Gda´nsk.

Registration is open until 30 September.

Meet Bioinnovation at Gda´nsk The organising commit­ tees of Bio­innovation In­ ternational Summit and ScanBalt Forum have joined their efforts to run an exceptional event – the Bioinnovation & ScanBalt

38_EBSIN8_13_SPECIAL_ScanBalt_2013_tg.indd 38

Andrzej Sieradzan Pro-Science Poland Ltd. Project Manager

Balt fmba, Gda´nsk Economic Development Agency Ltd. (InvestGDA), PRO-SCIENCE Po­ land Ltd. and Synergy Innovation Fund. The city of Gda´nsk, which is strongly focused on promotion of innovative projects, is a partner of the event. “Gda´nsk has always been the home of great innovators like Daniel Gabri­ el Fahrenheit. Today, we continue this tradi­ tion by supporting meetings like Bioinnova­ tion & ScanBalt Forum 2013,” says Gda´nsk Mayor Paweł Adamowicz. “The Pomerani­ an Voivodeship (Region) is one of the leading regions in the development of innovations in Eastern-Central Europe,” said Mieczysław Struk, Marshal of Pomeranian Voivodeship.

“When speaking about Life Science and Bio­ Business conferences, the Bioinnovation brand is one of our flagships.”

The organisers decided to prepare work­ shops tailored to the needs of the confer­ ence participants. “Writing successful sci­ entific papers” and “Effective management of a scientific team” will be conducted by representatives of Trans-Lite and PMExperts.

B

› Quick facts Key topics Presenting new trends in biotech­ nology Promoting Flagship EU projects and grants Advancing young scientists & PhD students Connecting science and business environments.

http://scanbaltforum2013.org/

08.08.2013 15:04:42 Uhr

Professor CHARLES CANTOR, the author of the first genomics handbook is going to be the KEYNOTE SPEAKER!

Register Now!

Registration opened till 30th September

• New trends in biotechnology • Flagship EU projects and grants • Connection of Scientific and Business environments

39_EBSIN8_13_BioinnovationScanbalt.indd 1

• Opportunity to present your scientific achievements to potential investors and partners

• Writing successful scientific papers • Effective management of a scientific team

08.08.2013 15:05:29 Uhr

40

Nº 8 | Volume 12 | 2013

Euro|Biotech|News

Euro Biofairs Compass

November 4 – 6, 2013 Messe Wien Exhibition and Congress Center, Vienna/Austria

Bio-Europe 2013

The partnering must Making contacts is key on the path to closing successful deals in the biopharma sector, and BIO-Europe® is the perfect place to make them. With more than 15,000 oneto-one meetings scheduled, it is the continent’s top networking event for the relevant players in biotechnology and pharma. This year it is taking place again in the important biotech hub of Vienna – the perfect backdrop for the 19th BIO-Europe.

The annual top partnering event is organised by EBD Group, the leading partnering firm for the global biotechnology industry, in alliance with the Biotechnology Industry Organization (BIO). Host sponsor is the Vienna life science cluster organisation LISA Vienna. This year´s BIO-Europe will see more than 3,000 industry attendees from over 50 countries, representing close to 1,800 companies during three days of high level networking. Partici-

pants from established and emerging biotech and pharma companies, professional services, institutional financial firms and other fields all flock to the event. The programme offers panel sessions and highlevel workshops, where experts on global biotech issues share their insights and opinions on various important industry topics. Attendees can also catch up on innovative technologies at the exhibition and at company presentations. But

Greeting

the form of biopharma partnering – is the most expedient strategy to fill drug pipelines. BIO-Europe® 2013 is a dedicated life science partnering forum, bringing together executives from pharma, large biotech and investment firms with global biotech.

International dealmakers engage in over 15,000 one-to-one partnering meetings there, making BIO-Europe one of the most productive partnering events in the world.

Join us in Vienna from November 4–6!

Join global dealmakers The key drivers of innovation are collaboration, a deep understanding of diseases and current treatment needs, and market intelligence. Of these, collaboration – in

40_EBSIN8_13_SPECIAL_BIO-Europe_2013_bs.indd 40

Florian Schoenhammer Managing Director, EBD Group

despite the variety, productive partnering remains the heart of the event. This year, over 15,000 one-to-one partnering meetings will be scheduled. The concept has proven itself time and again: Investment and collaboration opportunities developed at previous BIO-Europe conferences have produced many highly successful and international business partnerships. Organised with the support of BIO, this is regarded as a “must attend” event for the biotech industry. Partnering at BIO-Europe is powered by EBD Group’s partnering­ONE®, the industry’s most advanced networking system. It enables participants to efficiently mine a large pool of potential partners, and identify and pre­-arrange private one-to-one meetings with literally dozens of company targets.

Vienna has a long tradition of excellent life science research and business. The Austrian captial is home to 118 companies in the biotech and medtech sector, as well as 25 research institutions that employ more than 14,000 people.

› Quick facts Numbers 3,000 delegates and 1,800 companies from 50 countries Timeline 31 Aug: early registration deadline 23 Sep: online partnering starts Programme Schedule and registration www.ebdgroup.com/bioeurope

09.08.2013 13:01:10 Uhr

BUILDING VALUE THROUGH PARTNERSHIPS

BIO-EUROPE

®

19th Annual International Partnering Conference

2013

Register befor and save e August 31 E U R 20 0 !

NOVEMBER 4–6, 2013 VIENNA, AUSTRIA MESSE WIEN EXHIBITON & CONGRESS CENTER BIO-Europe® is Europe’s largest partnering conference, serving the global biotechnology industry. The conference annually attracts international leaders from biotech, pharma and finance along with the most promising start-ups and emerging companies. It is the “must attend” event for getting business done in the biotech industry.

Host Sponsor

BEU13 105 Biocom Ad 210x275.indd 1 41_EBSIN8_13_EBD.indd 1

© 2013 EBD GmbH Vienna image © WienTourismus/F 3

For further information, please view our conference website at www.ebdgroup.com/bioeurope

07.08.13 16:27 08.08.2013 15:06:19 Uhr

42

Nº 8 | Volume 12 | 2013

Euro|Biotech|News

Euro Biofairs Compass

December 9 – 10, 2013 Cámara de Comercio de Bogotá Bogotá / Colombia

Biolatam 2013

Greeting

Uncharted biowaters

Have an impact in Latin America

In early December – when Europe is suffering from cold, damp weather – it’s a great time to head for warmer climes! With temperatures averaging over 20 degrees Celsius and three times as many hours of sun as central Europe, Bogotá is preparing to welcome guests from all over the world to the BIOLATAM 2013 partnering event and conference. Organised for the first time, the event is aiming to become the global event for biotechnology in Latin America.

BIOLATAM 2013 will combine conferences, business meetings and networking events to facilitate contacts between international companies, investors, entrepreneurs and research centres in the field of biotechnology and related areas. At this first edition, attendance is expected to exceed 500 participants. International delegations from more than 20 different countries are expected to come to Bogotá.

› Quick facts When?

9-10 December 2013 Where?

Salitre Office, Chamber of Commerce Calle 26 No.68 D35 Bogotá / Colombia Phone: +34 912 109 374 biolatam2013@biolatam.org www.biolatam.org/

42_EBSIN8_13_SPECIAL_BIOLATAM_Compass_Herbst 2013_ml.indd 42

The conference will start off with a seminar on corporate venture capital in the Latin American entrepreneur ecosystem. That will be followed up by a section of special importance to Latin American countries, which are heavily focussed on agricultural products – the advent of a biobased economy and the chances emerging for the region in the fields of biofuels and bioplastics. Conference streams on medical biotechnology will focus on personalised medicine, biosimilars, advanced therapies, and in­­-vitro diagnostics for infectious diseases. Other topics will include food biotechnology, agrobiotechnology, health products, cosmetics, biodiversity and animal health.

At the conference there will be always opportunities for face-to-face meetings.

Partnering is the key to promoting business between biotechnology companies, as well as between them and the consumer sectors (pharmaceutical, sanitation products, foodstuffs, energy, etc.) from all over the world that have specific interests in Latin America.

B

Biolatam is a partnering forum with a global reach and a Latin American focus that will be held biennially in oddnumbered years.

We are seeking to become the leading event for the biotechnology sector in Latin America, as well as for the promotion of business opportunities among biotechnology companies from all over the world whose specific interests are aimed at this region. The forum would also like to be the meeting point for the Latino community with relevant positions in the industry around the world.

Biolatam welcomes companies, public institutions and venture capital (VC). The conference programme will cover different areas of biotechnology, especially those with the greatest potential to create an economic and social impact in Latin America. The event is also the perfect place to promote and strengthen relationships between investors and VC funds with origins or an interest in the Latin American market.

It’s a major event you can´t afford to miss.

We look forward to meeting you in Bogotá!

Regina Revilla Pedreira President of Spanish Bioindustry Association (ASEBIO)

08.08.2013 15:06:38 Uhr